Dr. Jack Vanden Heuvel discusses the use of cell-based reporter assays for nuclear receptor profiling to efficiently prioritize drug candidates and minimize off-target effects.

In preclinical drug discovery, the identification of potential drug candidates requires a thorough evaluation of their pharmacological effects, as well as any potential off-target liabilities. Nuclear receptors play a crucial role in many physiological processes and have emerged as important targets for drug discovery. However, potential drugs often have multiple effects, often within a gene family, leading to potential polypharmacology, where new beneficial effects, as well as off-target liabilities, can be discovered.

To triage or prioritize data, dose-response experiments with nuclear receptor assays can be used. In this presentation, we discuss the use of cell-based reporter assays for nuclear receptor profiling and how this strategy can help identify potential drug candidates with desirable pharmacological properties and reduced off-target effects.

Key Topics Include:

  • Understand the principles and advantages of using cell-based reporter assays for nuclear receptor profiling, including the ability to evaluate the potency, selectivity, and potential off-target effects of drug candidates
  • Learn about the different types of cell-based assays that can be used to triage compounds in the drug discovery pipeline with safety liabilities
  • Discover how nuclear receptor profiling can help identify potential drug candidates with desirable pharmacological properties

Presenters

Professor
Veterinary and Biomedical Sciences
Penn State University

Dr. Vanden Heuvel is a recognized expert in the field of nuclear receptor biology and toxicology with over 100 peer-reviewed publications. In addition to his role as Founder and Chief Scientific Officer at INDIGO Biosciences, Dr. Vanden Heuvel is a Professor of Molecular Toxicology at Penn State University

Production Partner

INDIGO Biosciences

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and in vitro toxicology solutions that accelerate scientific decision-making. We have been providing screening services and turnkey reporter assay kits to companies in the pharmaceutical, biotechnology, food, agriculture, and nutraceutical industries, as well as government agencies and academic researchers for over 15 years. We supplement the world’s largest portfolio of nuclear receptor assay kits and services and in vitro toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms, aim to reduce the time, cost, and risk associated with the discovery process.

Related Content